Pharmacokinetic and Dynamic correlation for optimum therapy of NTBC for the Treatment of Indian Patients with Hereditary Tyrosinemia type 1
Temp 2
DST
March 29, 2023
None
None
Hereditary Tyrosinemia type 1
In vitro study
Quantitative data
• To develop generic NTBC at significantly lower price compared to the presently imported products.
• To evaluate the efficacy and safety of indigenously manufactured generic Nitisinone.
• To establish the minimum dose of NTBC effective in suppressing the production of plasma succinyl acetone.
• The intended consumable tablet will be more temperature resistant compared to the internationally available exorbitant alternatives and will be more suitable to the Indian patients.
Pharmacokinetics, NTBC, Hereditary tyrosinemia type 1, Nitisinone
None
None
Dr. Neerja Gupta/None/Division of Genetics , AIIMS, New Delhi